From: Whole exome sequencing reveals novel somatic alterations in neuroblastoma patients with chemotherapy
No. | Age Month | Gender | Primary site | BM | N-MYC amplification | Tumor reduction | FU | Outcome | |
---|---|---|---|---|---|---|---|---|---|
RE1 | RE2 (%) | ||||||||
1 | 39 | F | R | Y | N | 80% | 94 | 14 | CR |
2 | 28 | F | R | Y | Y | 53% | 63 | 17 | Dead |
3 | 30 | M | R | Y | Y | 94% | 99 | 12 | Dead |
4 | 24 | F | R | Y | Y | 70% | 91 | 19 | CR |
5 | 84 | M | R | Y | Y | 0% | 0 | 17 | PR |
6 | 38 | F | R | Y | Y | 51% | 60 | 20 | PR |
7 | 61 | F | R | Y | N | 41% | 64 | 16 | PR |
8 | 36 | M | P | Y | Y | 79% | 79 | 18 | PR |
9 | 39 | F | R | Y | Y | 72% | 77 | 18 | PR |
10 | 19 | F | R | N | N | 88% | 93 | 21 | PR |
11 | 78 | M | R | Y | N | 70% | 89 | 25 | PR |
12 | 30 | M | R | N | Y | 47% | 82 | 14 | Dead |
13 | 40 | F | R | N | N | 49% | 57 | 13 | PR |
14 | 19 | F | R | N | N | 63% | 50 | 6 | Dead |
15 | 59 | F | R | Y | N | 86% | 99 | 22 | CR |
16 | 49 | M | P | N | Y | 60% | 97 | 13 | Dead |
17 | 39 | M | R | Y | N | 75% | 86 | 16 | PR |
18 | 48 | M | R | Y | Y | 29% | 35 | 18 | PR |
19 | 23 | F | R | Y | Y | 25% | 50 | 5 | Dead |
20 | 54 | F | R | Y | N | 50% | 60 | 13 | PR |
21 | 69 | F | R | Y | N | 60% | 80 | 14 | VGPR |
22 | 41 | F | R | N | N | 0 | 22 | 15 | PR |
23 | 101 | M | P | Y | N | 0 | 15 | 20 | Stable |
24 | 61 | M | R | Y | Y | 71% | 92 | 20 | CR |
25 | 36 | F | R | Y | N | 50% | 81 | 19 | VGPR |
26 | 15 | M | R | Y | N | 67% | 96 | 21 | CR |
27 | 31 | M | R | Y | Y | 71% | 95 | 14 | Dead |